In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Aradigm Corporation. Trade Record

NASDAQ:ARDM Aradigm Corporation stock gains 16.45% Exit Jun 21, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ARDM Jun 1, 2018, priceSeries
About Aradigm Corporation

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases. The company's lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, such as non-cystic fibrosis bronchiectasis (BE) and cystic fibrosis (CF). It is conducting a Phase III clinical trials with Pulmaquin in BE; and Phase IIb trial with Lipoquin and Pulmaquin in BE. The company has also completed a Phase IIa trial with Lipoquin in CF and Phase IIa trial with Lipoquin in BE. Its proprietary program under development is ARD-1600 Inhaled Nicotine, a smoking cessation therapy. The company has collaboration agreements with Oregon State University and Grifols, S.A. Aradigm Corporation was founded in 1991 and is headquartered in Hayward, California.

Trade Information
Trade Type
LONG
ReliabilityScore™
78.99
Entry Date
Jun 1, 2018
Entry Price
1.46
Sell Date
Jun 21, 2018
Sell Price
1.70
Net Gain
16.45%
Hold Time
14 Trading Days